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LABORATORY INVESTIGATION
Excess parathyroid hormone adversely affects lipid metabolism
in chronic renal failure
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Division of Nephrology and the Department of Medicine, the University of Southern California School of Medicine, Los Angeles, California,
and the Division of Endocrinology and Department of Medicine, Wayne State University, Detroit, Michigan, USA
Excess parathyroid hormone adversely affects lipid metabolism in
chronic renal failure. Hyperlipidemia is common in chronic renal failure
(CRF), but the underlying mechanisms are not clearly defined. Certain
data points toward a potential role for the state of secondary hyper-
parathyroidism of CRF in its pathogenesis. We examined the effects of
parathyroid hormone (PTH) on lipid metabolism utilizing intravenous
fat tolerance test (IVVFT) and post-heparin lipolytic activity in five
normal dogs, in six animals with CRF and secondary hyperparathyroid-
ism (NPX) and in six normocalcemic-thyroparathyroidectomized dogs
(NPX-PTX) with comparable degree and duration of CRF. NPX dogs
had fasting hypertriglyceridemia (82 + 6.0 mg/dl vs. 49 2.7 mgldl in
normal dogs, P < 0.01), abnormal IVFTT, and reduced post-heparin
plasma LPL activity (151 10 vs. 275 15 mol fatty acids/mI/mm in
normal dogs, P < 0.01). The NPX-PTX dogs had normal fasting levels
of serum triglycerides (42 0.6 mg/dl), normal IVFTT, and normal
post-heparin plasma LPL (317 19 prnol fatty acids/mi/mm) despite
CRF. Post-heparin HL activity in plasma was not different between
NPX and NPX-TPX dogs. The results show that excess blood levels of
PTH and not other consequences of CRF are mainly responsible for the
abnormalities in lipid metabolism. The data are consistent with the
notion that excess PTH reduces post-heparin LPL activity in plasma,
which in turn results in impaired lipid removal from the circulation and
consequently hyperlipidemia.
Abnormalities in lipid metabolism are commonly encoun-
tered in patients with chronic renal failure (CRF) [1—3]. These
patients have hypertriglyceridemia due to an increase in triglyc-
erides contained in the very low density, intermediate density
and low density lipoproteins. Serum cholesterol is usually
normal [1, 21. The mechanisms responsible for the hyperlipi-
demia of CRF are not well delineated. CRF is associated with
many metabolic abnormalities such as hyperphosphatemia [41,
hypocalcemia [4], low blood levels of 1,25 dihydroxyvitamin D
[5], hyperinsulinemia and peripheral resistance to the action of
insulin [6] and secondary hyperparathyroidism [7, 81. Each or a
combination of these derangements could play a role in the
genesis the hyperlipidemia of CRF [9—11].
Certain data suggest that excess PTH may induce distur-
bances in lipid metabolism. First, Cantin [9] found that removal
of the parathyroid glands partially inhibited the rise in blood
lipids observed after acute renal failure produced by bilateral
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nephrectomy, and the administration of parathyroid extract to
parathyroidectomized nephrectomized rats restored the hyper-
lipidemia. However, he did not examine the mechanisms un-
derlying his observations. Second, secondary hyperparathy-
roidism in rats produced either by feeding them low calcium
diet or by administration of parathyroid extracts was associated
with hypertriglyceridemia [10], but the role of excess PTH in
the hyperlipidemia of CRF was not examined. In contrast,
others could not document a rise in serum triglyceride levels or
a rise in tissue lipoprotein lipase after 15 hours of parathyroid
extract administration to rats [12]. Third, Heuck et al [13] also
found that parathyroidectomy ameliorated the hyperlipidemia
in rats with CRF of five weeks duration. Fourth, Ljunghall et al
[14] found type IV hyperlipoproteinemia in a large number of
patients with primary hyperparathyroidism. Fifth, Lacour et al
[15] reported that patients with both primary and secondary
hyperparathyroidism display disturbances in serum lipids which
could be corrected after parathyroidectomy. In contrast, Vaziri
et al [16] did not find abnormal serum lipid levels in patients
with primary hyperparathyroidism and removal of the parathy-
roid adenoma did not affect serum lipid levels.
Although the available data may implicate excess PTH in the
genesis of the hyperlipidemia of CRF, it is possible that
another, as yet unidentified, factor(s) responsible for the hyper-
lipidemia accumulates in the blood of CRF patients as PTH
does, and that the elevated blood levels of PTH represents an
index for the levels of this other compound(s). In addition,
other metabolic derangements in CRF mentioned above may
also play a role.
In order to definitely incriminate PTH in the genesis of the
hyperlipidemia in CRF, one must document that the blood
levels of lipids are normal and the mechanisms underlying the
hyperlipidemia are corrected in CRF without excess PTH. The
present study was undertaken to examine these questions.
Methods
A total of 17 female mongrel dogs weighing 16 to 22 (18
0.40) kg were studied. All dogs were subjected to episiotomy to
permit easy access to the bladder for the measurement of
creatinine clearance in the awake state. The animals received
the same diet providing 78 g of protein, 60 g of fat and 5 g of
calcium, and 3 g of phosphorus per day (Kal-Kan, Kal-Kan
Food Company, Inc., Vernon, California, USA).
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Renal failure was produced in 12 dogs by two-stage 5/6
nephrectomy. First, the animals underwent left subtotal ne-
phrectomy by ligation of five of the six branches of the left renal
artery. At the same time, 6 of the 12 dogs also had thyropara-
thyroidectomy (PTX). The success of PTX was ascertained by
a fall in plasma concentration of calcium of at least 2 mg/dl. The
diet of the PTX dogs was initially supplemented with 5 g of
calcium carbonate per day to achieve normocalcemia. After
serum calcium was normalized, the dogs received 3 g of calcium
carbonate per day. These PTX dogs also received an oral dose
of L-thyroxine of 0.1 mg daily for five days per week. Three
weeks later all 12 animals were subjected to right nephrectomy.
Thus, this protocol provided two groups of dogs with chronic
renal failure (CRF): one with intact parathyroid glands (NPX)
and the other without parathyroid glands (NPX-PTX). All
animals were followed carefully thereafter for more than one
year. We did not encounter difficulty in maintaining NPX and
NPX-PTX dogs and the mortality was about 15%. A third group
of five normal dogs was also studied.
Intravenous fat tolerance test (IVFTT)
This test was performed after 16 hours overnight fast in five
normal dogs, in five NPX dogs (after 54.0 0.73 weeks of CRF)
and in six NPX-PTX animals (after 53.7 0.80 weeks of CRF).
The dogs received a rapid intravenous injection of 20% Intra-
lipid (Kabi Vitrum, Alameda, California, USA) 0.5 mI/kg body
weight; this is equivalent to 0.1 g triglyceride/kg body weight.
Blood samples were obtained prior to and at 3, 5, 10, 20, 30, 40,
50 and 60 minutes after the injection of the Intralipid. The blood
samples were collected in EDTA containing tubes, centrifuged
immediately at 4°C and kept frozen at —70°C until the measure-
ment of triglycerides were made.
Post-heparin lipolytic activity
This test was done in all 17 dogs. At least two weeks
separated the test from IVFTT. Each animal received a bolus
injection of 100 U heparin/kg body weight. Blood samples were
obtained at 5, 10, 15, 20 and 30 minutes after the injection of
heparin. The samples were collected in EDTA-containing
tubes, centrifuged immediately at 4°C and stored at —70°C until
the assay was made.
The post-heparin lipoprotein lipase (LPL) activity in plasma
was measured in duplicate as described in [161 using specific
substrates prepared by sonicating [3H] trioleoylglyceride with
lysophosphatidyicholine. In three NPX and three NPX-PTX
dogs both LPL and hepatic lipase (HL) were measured. Serum
triglycerides were determined enzymatically. The concentra-
tions of phosphorus, creatinine and cholesterol were measured
by an autoanalyzer (Technicon Instrument Corp., Tarrytown,
New York, USA), those of calcium by an atomic absorption
spectrophotometer model 503 (Perkin-Elmer, Corp., Norwalk,
Connecticut, USA), PTH was determined with radioimmuno-
assay using sheep antibody 478 (supplied by Dr. Claud Arnaud),
1251-labeled bovine PTH, and pooled sera from dogs with CRF
as standard. This antibody reacts predominatly with an immu-
nological determinant in the carboxy-region of PTH, and it will
detect both intact hormone and its carboxy-terminal fragment.
The details of this assay for canine serum have been reported
previously from our laboratory [171. T4 and T1 were measured
by radioimmunoassays validated for canine serum [18].
Table 1. Biochemical data in control, NPX and NPX-PTX dogs
Control NPX NPX-PTX
Weight, kg 18.7 0.9 18.4 0.9 18.7 0.2
Duration of CRF, weeks — 54.0 0.7 53.0 0.8
Creatinine clearance 57.0 1.1 10.0 1.5k 11.0 1.8°
mi/mm
Fasting serum triglycerides 49.0 2.7 82.0 6.0° 42.0 6.0
mg/di
Fasting serum cholesterol 219 20 242 14 236 20
mg/d/
Plasma calcium ing/dI 10.1 0.20 10.0 0.22 10.1 0.23
Plasma phosphorus mg/dl 3.5 0.20 3.8 0.34 4.0 0.14
Serum PTH pJEq/ml 17.0 1.2 124 7.2a UDb
SerumT4pg/di 1.20±0.14 1.25±0.15 1.19±0.10
Serum T3 ng/di 37 4.2 43 8.2 37 8.9
Data are mean SE.
P < 0.01 vs. controlb UD, undetectable
Statistical analysis was done with the Clinfo computor sys-
tem. The data are presented as mean SE. Changes from
baseline in the parameter with multiple measurements with time
(serum triglycerides levels after Intralipid injection) were eva!-
uated by calculating area under the curve for each experiment
utilizing the trapezoidal rule. The area under the curve were
analyzed by one-way analysis of variance and compared with
each other using the Duncan multiple range test. In the calcu-
lation of the area under the curve, the change from baseline for
each data point was used. The fractional clearance rate (K2%/
mm) of triglyceride was calculated according to Lewis eta! [19].
The statistical significance of the PHLA activity, fasting serum
triglyceride levels and other biochemical parameters was eva!-
uated by unpaired t-test.
Results
The biochemical data of the various groups of dogs are
presented in Table 1. The 5/6 nephrectomy resulted in a
significant (P < 0.01) decrease in creatinine clearance both in
NPX (from 57.8 1.0 to 10.5 1.5 ml/min) and in NPX-PTX
dogs (from 56.7 1.3 to 11.0 1.8 mllmin). The values at the
time of the study were significantly (P < 0.01) lower than those
in the control dogs (57.1 1.1 mI/mm). There were no signifi-
cant differences in the plasma concentrations of calcium and
phosphorus, and in serum T4 and T3 among the three groups of
dogs. The serum levels of PTH were markedly elevated in NPX
dogs (124 7 piEq/ml) and were significantly higher than those
in normal dogs (17 1.2 piEq/ml). There was no detectable
PTH in the serum of NPX-PTX dogs.
After more than one year of CRF, the NPX dogs had normal
serum levels of cholesterol but significantly (P < 0.01) higher
serum triglycerides levels (82 6.0 mg/dl) than both the normal
animals (49 2.7 mg/dl) and the NPX-PTX dogs (42 6.0
mg/dl). The values in the normal and NPX-PTX dogs were not
statistically different.
The changes in the serum levels of triglycerides during the
IVFTT in the three groups of dogs studied are given in Figure 1.
Within three minutes after Intralipid injection, the serum levels
of the triglycerides reached their peak and decreased thereafter.
NPX dogs with intact parathyroid glands and elevated blood
levels of PTH displayed fat intolerance with the serum levels of
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Fig. 1. The changes in serum triglyceride
concentrations during IVFTT. Each data point
60 represents the mean value and bracketsdenote 1 SE. Symbols are: (O—O) control;(• •) NPX; (A—A) NPX-PTX.
Table 2. Post
-heparin lipoprotein lipase activity in plasma
NPX and NPX-PTX dogs
in control,
Time mm
LPL jsmol fatty acids/mi/mm
5 10 15 20 30
Control dogs
NPX-dogs
NPX-PTX
dogs
230
124
270
18 267 20 266 28 274 26
l5 137 l3 141 ll 159 19
27 273 21 299 34 315 33
275
151
317
14
ica
19
triglycerides being significantly higher than those in normal
dogs and in NPX-PTX animals throughout the study. The area
under the curve during the IVFTT in NPX dogs (8673 949
mg 60 mm) was significantly (P < 0.01) greater than that in
normal dogs (4637 693 mg 60 mm) and in NPX-PTX animals
(5442 277 mg 60 mm). The values in normal and NPX-PTX
dogs were not statistically different. The fractional clearance
rate (K2 rate) of triglycerides showed values of 2.86 0.32%!
mm in normal dogs, 1.6 0.23%/mm in NPX dogs (P < 0.01),
and 2,42 0.23%/mm in NPX-PTX animals. The latter value is
significantly (P < 0.01) higher than in NPX dogs but not
different from normal.
The post-heparin LPL activity in plasma of NPX dogs was
lower than those in normal and NPX-PTX dogs throughout the
30 minutes of observation (Table 2) and the mean values of
NPX dogs (151 10 mol fatty acids!ml!min) was significantly
(P < 0.01) lower than that in normal (275 14 j.mol fatty
acids/ml!min) and NPX-PTX dogs (317 19 tmol fatty acid!
ml/min; Fig. 2). In the dogs where both LPL and HL activities
were measured, the post-heparin LPL levels in NPX-PTX dogs
(346 37.0 mol fatty acids/mllmin) were 2.8 times higher than
in NPX dogs (126 26.0 mol fatty acids/mi/mm), while the
HL levels in NPX-PTX (123 3.9 mol fatty acids!mllmin)
animals were only 1.3 higher than in NPX animals (97 33.6
E
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Data are presented as mean SE.
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Fig. 2. The mean values of plasma PHLA observed over the 30
minutes after the injection of heparin. These values represent LPL
activity only and does not include HL activity.
smol fatty acids/mi/mm); the values of HL activity was not
different between the two groups of dogs.
Discussion
The results of the present study demonstrate that CRF of
more than one year duration in dogs is associated with sponta-
neous fasting hypertriglyceridemia but normal levels of serum
cholesterol, fat intolerance and reduced post-heparin LPL
activity in plasma. Such findings are also observed in humans
with advanced CRF [1—3, 20], indicating that the dogs are
applicable to humans in that regard.
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Our data also show that these derangements are reversed in
dogs with CRF but without secondary hyperparathyroidism,
and that the fat intolerance, the hypertriglyceridemia and the
reduced post-heparin plasma levels of LPL in NPX dogs are
mainly related to the excess serum levels of PTH and not to
other consequences of renal failure.
It is theoretically possible that some other, as yet unidenti-
fied, compound(s) could also accumulate in the blood of dogs or
humans with CRF and may contribute to or cause the derange-
ments in lipid metabolism. This possibility seems remote unless
one postulates that the production and/or accumulation of such
a compound depends on excess PTH. Even if such a possibility
does exist, one must still conclude that excess serum levels of
PTFI are of major importance in the genesis of the hyperlipid-
emia of CRF.
A potential effect of other metabolic derangement of CRF or
of our experimental procedure on the results of our studies
should be considered. First, alterations in serum levels of
calcium and phosphorus could affect lipid metabolism [11]. Our
observation on lipid metabolism in NPX and NPX-PTX dogs
could not be attributed to variations in the serum levels of
calcium and phosphorus since these latter parameters were not
significantly different between the two groups nor from those
observed in the normal animals. Second, high doses of vitamin
D given to humans was associated with a rise in serum
cholesterol without changes in triglycerides [11]. Although both
NPX and NPX-PTX dogs would have low blood levels of
1,25(OH)2D, these levels may be higher in NPX dogs than in
NPX-PTX animals since PTH stimulates l,25(OH)2D produc-
tion [21]. Based on the human studies cited above [11] the
differences in blood levels of 1 ,25(OH)2D between our NPX and
NPX-PTX should have caused a rise in serum cholesterol in
NPX dogs without effect on serum triglycerides. Our findings
do not support such a prediction. Finally, it is theoretically
possible that the administration of thyroid hormones to the
NPX-PTX dogs caused a state of hyperthyroidism which in turn
could have affected lipid metabolism in these animals. This
seems unlikely since the serum levels of T4 and T3 in the
NPX-PTX dogs were not significantly different from those in
NPX or in normal dogs.
Hypertriglyceridemia in CRF could result from increased
production, decreased removal or both. Available data indicate
that reduced removal is the major cause of the hypertriglycer-
idemia of CRF [3]. Our observations are consistent with the
notion that the action of excess PTH is mediated via a decrease
in post-heparin LPL activity resulting in reduction in triglycer-
ide removal from the circulation.
The mechanism through which excess PTH reduces post-
heparin LPL activity are not defined by our study. Excess PTH
may reduce the synthesis of LPL, may interfere with their
activator(s), may act as an inhibitor and/or stimulate the syn-
thesis of an inhibitor.
Insulin is essential for the synthesis of LPL [221. Therefore,
insulin deficiency and/or resistance to its action may contribute
to a deficiency in LPL and hence to reduced PHLA. Indeed,
infusion of insulin to CRF rats reversed the abnormalities in
LPL activity and in lipid metabolism [23]. We have previously
reported that for any given level of blood glucose, insulin levels
were significantly higher in NPX-PTX dogs than in NPX-dogs
[17]. Further, glucose-induced insulin release from pancreatic
islets obtained from NPX-rats is significantly and markedly
lower than insulin release from islets obtained from NPX-PTX
rats [24]. Thus, it appears that excess PTH impairs insulin
release from pancreas resulting in absolute or relative insulin
deficiency which reduces LPL synthesis. Such a link between
the effect of excess PTH on carbohydrate and lipid metabolism
seems plausible. It provides for at least one pathway through
which excess PTH may affect PHLA in CRF. Another possi-
bility that excess PTH may inhibit LPL is by generation of
increased intracellular levels of cyclic cAMP since the latter
may inhibit LPL activity [25].
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